Fathi, A., Erba, H., Lancet, J., Stein, E., Ravandi, F., Faderl, S., … Stein, A. (2016). SGN-CD33A IN COMBINATION WITH HYPOMETHYLATING AGENTS: A NOVEL, WELL-TOLERATED REGIMEN WITH HIGH REMISSION RATE IN OLDER PATIENTS WITH AML. In HAEMATOLOGICA (Vol. 101, pp. 186–187). Copenhagen, DENMARK: FERRATA STORTI FOUNDATION.

Fathi, A., H. Erba, J. Lancet, E. Stein, F. Ravandi, S. Faderl, R. Walter, et al. “SGN-CD33A IN COMBINATION WITH HYPOMETHYLATING AGENTS: A NOVEL, WELL-TOLERATED REGIMEN WITH HIGH REMISSION RATE IN OLDER PATIENTS WITH AML.” In HAEMATOLOGICA, 101:186–87. FERRATA STORTI FOUNDATION, 2016.

Fathi A, Erba H, Lancet J, Stein E, Ravandi F, Faderl S, et al. SGN-CD33A IN COMBINATION WITH HYPOMETHYLATING AGENTS: A NOVEL, WELL-TOLERATED REGIMEN WITH HIGH REMISSION RATE IN OLDER PATIENTS WITH AML. In: HAEMATOLOGICA. FERRATA STORTI FOUNDATION; 2016. p. 186–7.

Fathi, A., et al. “SGN-CD33A IN COMBINATION WITH HYPOMETHYLATING AGENTS: A NOVEL, WELL-TOLERATED REGIMEN WITH HIGH REMISSION RATE IN OLDER PATIENTS WITH AML.” HAEMATOLOGICA, vol. 101, FERRATA STORTI FOUNDATION, 2016, pp. 186–87.

Fathi A, Erba H, Lancet J, Stein E, Ravandi F, Faderl S, Walter R, Advani A, DeAngelo D, Kovacsovics T, Jillella A, Bixby D, Levy M, O’Meara M, Ho P, Stein A. SGN-CD33A IN COMBINATION WITH HYPOMETHYLATING AGENTS: A NOVEL, WELL-TOLERATED REGIMEN WITH HIGH REMISSION RATE IN OLDER PATIENTS WITH AML. HAEMATOLOGICA. FERRATA STORTI FOUNDATION; 2016. p. 186–187.